Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal Fluid

Extracellular matrix metalloproteinase inducer (EMMPRIN, CD147) is an inducer of matrix metalloproteinases and has roles in leukocyte activation and migration. We reported previously that in MS and its animal model, experimental autoimmune encephalomyelitis, cell surface-associated EMMPRIN was signi...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 11; no. 10; p. e0163802
Main Authors Kaushik, Deepak K., Yong, Heather Y. F., Hahn, Jennifer N., Silva, Claudia, Casha, Steven, Hurlbert, R. John, Jacques, Francois H., Lisak, Robert, Khan, Omar, Ionete, Carolina, Larochelle, Catherine, Prat, Alex, Bar-Or, Amit, Yong, V. Wee
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 11.10.2016
Public Library of Science (PLoS)
Subjects
Online AccessGet full text
ISSN1932-6203
1932-6203
DOI10.1371/journal.pone.0163802

Cover

More Information
Summary:Extracellular matrix metalloproteinase inducer (EMMPRIN, CD147) is an inducer of matrix metalloproteinases and has roles in leukocyte activation and migration. We reported previously that in MS and its animal model, experimental autoimmune encephalomyelitis, cell surface-associated EMMPRIN was significantly elevated in leukocytes around inflammatory perivascular cuffs in the CNS. In this study we report that activated T-cells can secrete soluble form of EMMPRIN (sEMMPRIN) upon activation. As sEMMPRIN is also present in biological fluids, we determined whether sEMMPRIN is altered in the CSF and sera of MS subjects. Sera from individuals without neurological conditions served as controls, while CSFs collected from subjects undergoing discectomy, and without evidence of CNS pathology, were used as a comparator group. We found that serum levels of sEMMPRIN from clinically stable MS patients or other inflammatory conditions did not differ from control subjects. Paired serum and CSF samples demonstrated poor correlation of sEMMPRIN. Interestingly, sEMMPRIN levels were approximately 60% higher in CSFs compared to sera. sEMMPRIN CSF levels were significantly higher in secondary progressive compared to primary progressive subjects. Thus we conclude that measurement of sEMMPRIN in serum is not informative for disease activity in MS. The differential expression of sEMMPRIN in the CSF of primary and secondary progressive MS invites hypotheses of the still undefined roles of EMMPRIN in the CNS.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Conceptualization: VWY. Data curation: VWY DKK CS. Formal analysis: DKK VWY HYFY. Funding acquisition: VWY. Investigation: DKK JNH HYFY. Methodology: DKK JNH HYFY. Project administration: VWY. Resources: VWY SC RJH FHJ RL OK CI CL AP ABO. Software: DKK. Supervision: VWY. Validation: DKK. Visualization: DKK VWY. Writing – original draft: DKK. Writing – review & editing: DKK VWY.
Competing Interests: The authors declare no competing interests.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0163802